NCT00499135View on ClinicalTrials.gov

Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 22, 2007

Primary Completion Date

May 14, 2014

Study Completion Date

May 14, 2014

Conditions

Adult Solid NeoplasmClear Cell Renal Cell CarcinomaRecurrent Renal Cell CarcinomaStage III Renal Cell CancerStage IV Renal Cell Cancer

Interventions

OTHER

Computed Tomography

Correlative studies

OTHER

Fluorothymidine F-18

Correlative studies

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

OTHER

Positron Emission Tomography

Correlative studies

DRUG

Sunitinib Malate

Given PO

Trial Locations (1)

53792

University of Wisconsin Hospital and Clinics, Madison

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00499135 - Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors | Biotech Hunter | Biotech Hunter